Interpace Biosciences, Inc. filed its 10-K on Mar 27, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | -7.33% | -4.14% | +28.70% |
Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
Mar. 07 | Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+28.70% | 6.07M | |
-14.16% | 5.6B | |
+2.93% | 1.29B |
- Stock Market
- Equities
- IDXG Stock
- News Interpace Biosciences, Inc.
- Interpace Biosciences, Inc. Auditor Raises 'Going Concern' Doubt